Processa Pharmaceuticals, Inc.

NasdaqCM:PCSA 주식 보고서

시가총액: US$3.7m

Processa Pharmaceuticals 미래 성장

Future 기준 확인 0/6

Processa Pharmaceuticals's earnings are forecast to decline at 9.6% per annum. EPS is expected to grow by 53.4% per annum.

주요 정보

-9.6%

수익 성장률

53.4%

EPS 성장률

Pharmaceuticals 수익 성장23.7%
매출 성장률n/a
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트03 Oct 2024

최근 미래 성장 업데이트

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20
We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26
Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15
What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20
How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

수익 및 매출 성장 예측

NasdaqCM:PCSA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2025N/A-13N/AN/A1
12/31/2024N/A-12N/AN/A1
9/30/2024N/A-12-11-11N/A
6/30/2024N/A-10-9-9N/A
3/31/2024N/A-10-8-8N/A
12/31/2023N/A-11-8-8N/A
9/30/2023N/A-22-8-8N/A
6/30/2023N/A-26-10-10N/A
3/31/2023N/A-28-10-10N/A
12/31/2022N/A-27-10-10N/A
9/30/2022N/A-18-10-10N/A
6/30/2022N/A-15-8-8N/A
3/31/2022N/A-13-8-8N/A
12/31/2021N/A-11-9-9N/A
9/30/2021N/A-23-8-8N/A
6/30/2021N/A-23-7-7N/A
3/31/2021N/A-20-5-5N/A
12/31/2020N/A-19-3-3N/A
9/30/2020N/A-6-1-1N/A
6/30/2020N/A-4-2-2N/A
3/31/2020N/A-4-3-3N/A
12/31/2019N/A-4-3-3N/A
9/30/2019N/A-3-3-3N/A
6/30/2019N/A-3-3-3N/A
3/31/2019N/A-3-3-3N/A
12/31/2018N/A-4-4-4N/A
9/30/2018N/A-4-4-4N/A
6/30/2018N/A-4N/A-4N/A
3/31/2018N/A-3N/A-3N/A
12/31/2017N/A-2N/A-2N/A
12/31/2016N/A-2N/A-2N/A

애널리스트 미래 성장 예측

수입 대 저축률: PCSA is forecast to remain unprofitable over the next 3 years.

수익 vs 시장: PCSA is forecast to remain unprofitable over the next 3 years.

고성장 수익: PCSA is forecast to remain unprofitable over the next 3 years.

수익 대 시장: Insufficient data to determine if PCSA's revenue is forecast to grow faster than the US market.

고성장 수익: PCSA is forecast to have no revenue next year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: Insufficient data to determine if PCSA's Return on Equity is forecast to be high in 3 years time


성장 기업 발견